Quick Answer
Vivos Therapeutics, Inc. reported Gross Profit of $9.02 million for the year ending 2024.
- Vivos Therapeutics, Inc. showed an increase of +9.0% in Gross Profit from 2023 to 2024.
- This data is from Vivos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $2.42 million | Q2 2020: $2.73 million | Q3 2020: $2.58 million | Q1 2021: $2.69 million | Q2 2021: $3.62 million | Q3 2021: $3.18 million | Q1 2022: $2.55 million | Q2 2022: $2.59 million | Q3 2022: $2.50 million | Q1 2023: $2.34 million | Q2 2023: $2.10 million | Q3 2023: $1.75 million | Q1 2024: $1.94 million | Q2 2024: $2.65 million | Q3 2024: $2.33 million | Q1 2025: $1.51 million | Q2 2025: $2.11 million | Q3 2025: $3.94 million.
- Over the full 6 years of available data (2019 to 2024), Vivos Therapeutics, Inc.'s Gross Profit has grown by 4.2%.
- Historical annual values: Fiscal year 2024: $9.02 million | Fiscal year 2023: $8.27 million | Fiscal year 2022: $10.02 million | Fiscal year 2021: $12.60 million | Fiscal year 2020: $10.41 million | Fiscal year 2019: $8.66 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: